Limited options remain for successful empiric treatment of uncomplicated urinary tract infections (uUTIs) in the community
DUBLIN, Ireland and CHICAGO, June 21, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation antibiotics (oral and IV) to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced it will make multiple presentations at ASM Microbe 2019, being held in San Francisco from June 20-24, 2019
“The research we are presenting at ASM Microbe 2019 underscores the need for better care in the diagnosis and treatment of uUTIs,” said Michael Dunne, M.D., Chief Scientific Officer of Iterum Therapeutics. “In both an open label clinical study as well as a retrospective analysis of a leading U.S. health plan’s medical and pharmacy claims database, it was concluded that patients with uUTIs in the community treated with the most commonly prescribed antibiotic for that infection, ciprofloxacin, have a significantly greater rate of treatment failure when the organism is quinolone resistant.”
Dr. Dunne will moderate Session S339 – Pipeline Drugs to Treat Gram-negative Infections – and deliver a presentation titled “Sulopenem: An oral Thiopenem Antibiotic for the Treatment of Infections-associated Resistant Enterobacteriaceae” on June 23, 2019, at 1:30 p.m. PT in 306/307/308 South.
Iterum Therapeutics will also present three posters which will be displayed in the Exhibit and Poster Hall on June 21, 2019, from 10:30 a.m. to 5 p.m. PT. Details are as follows.
Title: Failure of Empiric Treatment of Uncomplicated Urinary Tract Infection (UTI) Associated with Resistant Pathogens
Session: P403 – CIV01 – Clinical Studies of Adult Infectious Diseases: Treatment of Drug-resistant Infections
Poster number: CIV-140
Presenter: Michael Dunne
Title: Clinical and Microbiologic Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Adult Women
Session: P404 – CIV01 – Clinical Studies of Adult Infectious Diseases: Urinary Tract Infections
Poster Number: CIV-147
Presenter: Michael Dunne
Title: Impact of Urine Analysis Methods in the Diagnosis of Uncomplicated Urinary Tract Infection
Session: P446 – CPHM03 – Diagnostic Bacteriology: UTI Testing
Poster Number: CPHM-846
Presenter: Stephen Aronin
The posters will be available after ASM Microbe 2019 under “Publications” in the Our Science section of the company’s website at www.iterumtx.com.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with oral and IV formulations. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit http://www.iterumtx.com.
This press release may contain forward-looking statements. These forward-looking statements include, without limitation, statements regarding the development, therapeutic and market potential of sulopenem. In some cases, forward-looking statements can be identified by words such as “may,” “believes,” “intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future,” “potential” or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum Therapeutics’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum Therapeutics’ control, including the uncertainties inherent in the conduct of clinical trials, clinical trial patient enrollment, availability and timing of data from clinical trials, changes in regulatory requirements or decisions of regulatory authorities, the actions of third-party clinical research organizations, suppliers and manufacturers, commercialization plans and timelines, if approved, and other factors discussed under the caption “Risk Factors” in its most recently filed Quarterly Report on Form 10-Q, and other documents filed with the SEC from time to time. Forward-looking statements represent Iterum Therapeutics’ beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum Therapeutics assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
Chief Financial Officer
Source: Iterum Therapeutics plc
Released June 21, 2019